<turbo-stream action="append" target="audio_clips_list"><template>
    <hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8806030-gynecologic-oncology-surgery-advances-are-propelled-by-minimally-invasive-techniques-with-ursula"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43193613/75x75/c 75w, https://audioboom.com/i/43193613/150x150/c 150w, https://audioboom.com/i/43193613/300x300/c 300w, https://audioboom.com/i/43193613/600x600/c 600w, https://audioboom.com/i/43193613/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d265a; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43193613/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep47: Gynecologic Oncology Surgery Advances Are Propelled by Minimally Invasive Techniques: With Ursula Matulonis, 
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In the inaugural episode of this new podcast series, Drs Matulonis and May discuss advances in gynecologic cancer surgery. 
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
19m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1763061614" data-format="short_date">Nov 13, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
19m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8805094-unique-challenges-characterize-treatment-outcomes-for-women-with-bladder-cancer-with-martha-k-t"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43188722/75x75/c 75w, https://audioboom.com/i/43188722/150x150/c 150w, https://audioboom.com/i/43188722/300x300/c 300w, https://audioboom.com/i/43188722/600x600/c 600w, https://audioboom.com/i/43188722/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d4073; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43188722/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep46: Unique Challenges Characterize Treatment Outcomes for Women With Bladder Cancer: With Martha K. Terris, MD, FACS
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Dr Terris discusses disparities in treatment and outcomes for women with bladder cancer and summarized reasons for this poor prognosis. 
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
5m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1762905329" data-format="short_date">Nov 11, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
5m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8804608-urothelial-esmo-2025-updates"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43132120/75x75/c 75w, https://audioboom.com/i/43132120/150x150/c 150w, https://audioboom.com/i/43132120/300x300/c 300w, https://audioboom.com/i/43132120/600x600/c 600w, https://audioboom.com/i/43132120/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #a6daf3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43132120/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep45: Urothelial ESMO 2025 Updates
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
OncLive partnered with Two Onc Docs to review updates from the 2025 ESMO Congress on bladder cancer management that may change guidelines.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
13m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1762820400" data-format="short_date">Nov 11, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
13m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8803571-research-innovations-spark-promise-for-broadening-the-hr-breast-cancer-armamentarium-post-cdk4-6"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43181129/75x75/c 75w, https://audioboom.com/i/43181129/150x150/c 150w, https://audioboom.com/i/43181129/300x300/c 300w, https://audioboom.com/i/43181129/600x600/c 600w, https://audioboom.com/i/43181129/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d4073; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43181129/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep44: Research Innovations Spark Promise for Broadening the HR+ Breast Cancer Armamentarium Post-CDK4/6 Inhibition: With Kevin Kalinsky, MD, MS, FASCO
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Dr Kalinsky discusses the treatment paradigm for HR-positive breast cancer post-CDK4/6 inhibition and the need for therapeutic advances in this setting.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
10m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1762539624" data-format="short_date">Nov 07, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
10m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8803168-arros-1-data-show-zidesamtinib-s-favorable-safety-profile-spark-discussion-to-clarify-its-role-i"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43090935/75x75/c 75w, https://audioboom.com/i/43090935/150x150/c 150w, https://audioboom.com/i/43090935/300x300/c 300w, https://audioboom.com/i/43090935/600x600/c 600w, https://audioboom.com/i/43090935/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d4073; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43090935/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep43: ARROS-1 Data Show Zidesamtinib&#39;s Favorable Safety Profile, Spark Discussion to Clarify Its Role in ROS1+ NSCLC: With Stephen Liu, MD
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Dr Liu discusses the potential role for zidesamtinib for the treatment of patients with advanced non–small cell lung cancer harboring ROS1 rearrangements.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
11m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1762464300" data-format="short_date">Nov 06, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
11m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8803157-dynamic-frailty-assessment-underscores-need-for-ongoing-evaluation-in-transplant-ineligible-multi"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43179019/75x75/c 75w, https://audioboom.com/i/43179019/150x150/c 150w, https://audioboom.com/i/43179019/300x300/c 300w, https://audioboom.com/i/43179019/600x600/c 600w, https://audioboom.com/i/43179019/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d4073; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43179019/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep42: Dynamic Frailty Assessment Underscores Need for Ongoing Evaluation in Transplant-Ineligible Multiple Myeloma: With Hira Mian, MD, MSc, FRCPC
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Dr Mian discussed why frailty should be understood as a dynamic, evolving clinical state rather than a fixed baseline characteristic
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
5m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1762463829" data-format="short_date">Nov 06, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
5m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8802719-patient-reported-outcomes-show-benefits-of-isatuximab-on-body-injector-in-myeloma-with-sikander"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43176782/75x75/c 75w, https://audioboom.com/i/43176782/150x150/c 150w, https://audioboom.com/i/43176782/300x300/c 300w, https://audioboom.com/i/43176782/600x600/c 600w, https://audioboom.com/i/43176782/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d4073; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43176782/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep41: Patient-Reported Outcomes Show Benefits of Isatuximab On-Body Injector in Myeloma: With Sikander Ailawadhi, MD, and Beth Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Ailawadhi and Faiman discuss the rationale for efforts to bring isatuximab on-body injectors into the clinic for patients with multiple myeloma. 
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
19m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1762386600" data-format="short_date">Nov 05, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
19m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8801098-bladder-cancer-symptom-awareness-and-testing-are-crucial-for-early-detection-in-women-with-marth"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43168487/75x75/c 75w, https://audioboom.com/i/43168487/150x150/c 150w, https://audioboom.com/i/43168487/300x300/c 300w, https://audioboom.com/i/43168487/600x600/c 600w, https://audioboom.com/i/43168487/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d4073; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43168487/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep40: Bladder Cancer Symptom Awareness and Testing Are Crucial for Early Detection in Women: With Martha K. Terris, MD, FACS
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Closing the Gap: Understanding Gender Disparities in Bladder Cancer Care, hosted by Martha K. Terris, MD, FACS, is a limited series spotlighting unique considerations for bladder cancer diagnosis and treatment among women. Dr Terris is department chair and a professor in the Department of Urology, the Witherington Distinguished Chair in Urology, and co-director of the Cancer Center at the Medic...
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
5m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1762290174" data-format="short_date">Nov 04, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
5m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8800693-oncology-experts-dive-into-top-data-from-esmo-2025"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43168058/75x75/c 75w, https://audioboom.com/i/43168058/150x150/c 150w, https://audioboom.com/i/43168058/300x300/c 300w, https://audioboom.com/i/43168058/600x600/c 600w, https://audioboom.com/i/43168058/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d4073; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43168058/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep39: Oncology Experts Dive Into Top Data From ESMO 2025
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
At the 2025 ESMO Congress, leading oncologists reflected on data expected to redefine practice across breast, genitourinary, and gynecologic malignancies.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
18m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1762214719" data-format="short_date">Nov 04, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
18m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8798654-ongoing-adt-use-and-research-emphasizes-the-importance-of-shared-decision-making-in-prostate-canc"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43155611/75x75/c 75w, https://audioboom.com/i/43155611/150x150/c 150w, https://audioboom.com/i/43155611/300x300/c 300w, https://audioboom.com/i/43155611/600x600/c 600w, https://audioboom.com/i/43155611/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d4073; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43155611/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep38: Ongoing ADT Use and Research Emphasizes the Importance of Shared Decision-Making in Prostate Cancer Care: With Neal Shore, MD, FACS
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Dr Shore discusses the use of ADT in patients with prostate cancer, as well as toxicities and quality-of-life complications associated with these agents.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
12m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1761953118" data-format="short_date">Oct 31, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
12m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8798113-early-detection-surgical-innovation-and-multidisciplinary-collaboration-evolve-lung-cancer-care"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43153022/75x75/c 75w, https://audioboom.com/i/43153022/150x150/c 150w, https://audioboom.com/i/43153022/300x300/c 300w, https://audioboom.com/i/43153022/600x600/c 600w, https://audioboom.com/i/43153022/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d4073; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43153022/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep37: Early Detection, Surgical Innovation, and Multidisciplinary Collaboration Evolve Lung Cancer Care: With Ziad Hanhan, MD, Thomas Bauer, MD, and Rachel NeMoyer, MD
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Drs Hanhan, Bauer, and NeMoyer discuss the ins and outs of lung cancer diagnosis, surgical management, and evolving treatment paradigms. 
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
29m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1761864018" data-format="short_date">Oct 30, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
29m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8797556-evolving-research-paradigms-real-world-data-and-multidisciplinary-collaboration-enhance-bladder"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43150283/75x75/c 75w, https://audioboom.com/i/43150283/150x150/c 150w, https://audioboom.com/i/43150283/300x300/c 300w, https://audioboom.com/i/43150283/600x600/c 600w, https://audioboom.com/i/43150283/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d4073; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43150283/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep36: Evolving Research Paradigms, Real-World Data, and Multidisciplinary Collaboration Enhance Bladder Cancer Management: With Amit Mehta, MD 
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Dr Mehta discussed practice-changing urothelial carcinoma data that have been presented throughout 2024 and 2025, the clinical utility of enfortumab vedotin plus pembrolizumab for select patients with advanced or metastatic urothelial cancer, and differing treatment approaches for patients with lymph node–only vs distant metastases.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
27m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1761767606" data-format="short_date">Oct 29, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
27m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8796560-fda-approval-insights-y-90-resin-microspheres-for-unresectable-hcc-with-armeen-mahvash-md"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43145188/75x75/c 75w, https://audioboom.com/i/43145188/150x150/c 150w, https://audioboom.com/i/43145188/300x300/c 300w, https://audioboom.com/i/43145188/600x600/c 600w, https://audioboom.com/i/43145188/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #8da6c0; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43145188/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep35: FDA Approval Insights: Y-90 Resin Microspheres for Unresectable HCC: With Armeen Mahvash, MD
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Dr Mahvash discusses the FDA approval of SIR-Spheres Y-90 resin microspheres for the treatment of patients with unresectable hepatocellular carcinoma. 
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
15m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1761597300" data-format="short_date">Oct 27, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
15m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8795384-fda-approval-insights-adjuvant-cemiplimab-for-high-risk-cscc-with-vishal-a-patel-md-faad-facms"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43139303/75x75/c 75w, https://audioboom.com/i/43139303/150x150/c 150w, https://audioboom.com/i/43139303/300x300/c 300w, https://audioboom.com/i/43139303/600x600/c 600w, https://audioboom.com/i/43139303/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #8da6c0; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43139303/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep34: FDA Approval Insights: Adjuvant Cemiplimab for High-Risk CSCC: With Vishal A. Patel, MD, FAAD, FACMS
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Dr Patel discusses the clinical relevance of the FDA approval of adjuvant cemiplimab for the management of high-risk cutaneous squamous cell carcinoma.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
12m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1761261945" data-format="short_date">Oct 23, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
12m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8795304-tumor-board-advances-in-managing-egfr-mutant-nsclc-applying-evidence-across-the-disease-continuum"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43138896/75x75/c 75w, https://audioboom.com/i/43138896/150x150/c 150w, https://audioboom.com/i/43138896/300x300/c 300w, https://audioboom.com/i/43138896/600x600/c 600w, https://audioboom.com/i/43138896/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d4073; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43138896/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep33: Tumor Board: Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In this podcast, experts Tina Cascone, MD, PhD; Christina Baik, MD, MPH; and David Planchard, MD, PhD discuss data-driven treatment for EGFR-mutant non-small cell lung cancer.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
33m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1761252480" data-format="short_date">Oct 23, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
33m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8794842-evolving-treatment-strategies-and-novel-therapies-reshape-secondary-aml-management-with-eunice-w"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43136645/75x75/c 75w, https://audioboom.com/i/43136645/150x150/c 150w, https://audioboom.com/i/43136645/300x300/c 300w, https://audioboom.com/i/43136645/600x600/c 600w, https://audioboom.com/i/43136645/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d4073; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43136645/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep32: Evolving Treatment Strategies and Novel Therapies Reshape Secondary AML Management: With Eunice Wang, MD
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Dr Wang discusses the prevalence of secondary AML, unmet needs for patients with this disease, and how CPX-351 has generated improved outcomes vs 7+3.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
13m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1761169807" data-format="short_date">Oct 22, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
13m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8793906-metastatic-breast-cancer-2025-update"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43132120/75x75/c 75w, https://audioboom.com/i/43132120/150x150/c 150w, https://audioboom.com/i/43132120/300x300/c 300w, https://audioboom.com/i/43132120/600x600/c 600w, https://audioboom.com/i/43132120/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #a6daf3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43132120/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep31: Metastatic Breast Cancer 2025 UPDATE
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In this episode, Two Onc Docs review the current management of metastatic breast cancer, emphasizing treatment strategies across molecular subtypes.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
12m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1760995200" data-format="short_date">Oct 20, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
12m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8792566-fda-approval-insights-subcutaneous-pembrolizumab-for-solid-tumors-with-j-thaddeus-beck-md-facp"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43125412/75x75/c 75w, https://audioboom.com/i/43125412/150x150/c 150w, https://audioboom.com/i/43125412/300x300/c 300w, https://audioboom.com/i/43125412/600x600/c 600w, https://audioboom.com/i/43125412/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #f3f3f3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43125412/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep30: FDA Approval Insights: Subcutaneous Pembrolizumab for Solid Tumors: With J. Thaddeus Beck, MD, FACP
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s episode, we had the pleasure of speaking with J. Thaddeus Beck, MD, FACP, about the FDA approval of pembrolizumab and berahyaluronidase alfa-pmph (subcutaneous pembrolizumab; Keytruda Qlex) for subcutaneous injection in adult and pediatric patients at least 12 years of age with solid tumors for which the intravenous formulation of pembrolizumab (Keytruda) is indicated.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
5m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1760642080" data-format="short_date">Oct 16, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
5m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8791922-passion-and-innovation-formed-the-foundation-for-a-leading-cancer-program-with-girindra-raval-m"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43122506/75x75/c 75w, https://audioboom.com/i/43122506/150x150/c 150w, https://audioboom.com/i/43122506/300x300/c 300w, https://audioboom.com/i/43122506/600x600/c 600w, https://audioboom.com/i/43122506/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d2640; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43122506/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep29: Passion and Innovation Formed the Foundation for a Leading Cancer Program: With Girindra Raval, MD; and Anand Jillella, MD
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Raval and Jillella discussed Jillella&#39;s career journey, starting from his oncology internship in 1989 to establishing a bone marrow transplant program. 
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
38m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1760570400" data-format="short_date">Oct 15, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
38m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8790848-oncology-experts-preview-key-studies-ahead-of-the-2025-esmo-congress"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43117351/75x75/c 75w, https://audioboom.com/i/43117351/150x150/c 150w, https://audioboom.com/i/43117351/300x300/c 300w, https://audioboom.com/i/43117351/600x600/c 600w, https://audioboom.com/i/43117351/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d4073; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43117351/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep28: Oncology Experts Preview Key Studies Ahead of the 2025 ESMO Congress
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Leading experts across oncology specialties preview the key studies and data they are most anticipating ahead of the 2025 ESMO Congress.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
13m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1760392200" data-format="short_date">Oct 13, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
13m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8789550-fda-approval-insights-gemcitabine-intravesical-system-for-nmibc-with-joseph-jacob-md-mcr"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43110876/75x75/c 75w, https://audioboom.com/i/43110876/150x150/c 150w, https://audioboom.com/i/43110876/300x300/c 300w, https://audioboom.com/i/43110876/600x600/c 600w, https://audioboom.com/i/43110876/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #8da6c0; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43110876/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep27: FDA Approval Insights: Gemcitabine Intravesical System for NMIBC: With Joseph Jacob, MD, MCR
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Dr Jacob discusses the significance of the FDA approval of the gemcitabine intravesical system for BCG-unresponsive non–muscle-invasive bladder cancer.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
12m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1760050813" data-format="short_date">Oct 09, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
12m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8788965-fda-approval-insights-sunvozertinib-in-egfr-mutated-metastatic-nsclc-with-lyudmila-bazhenova-md"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43107924/75x75/c 75w, https://audioboom.com/i/43107924/150x150/c 150w, https://audioboom.com/i/43107924/300x300/c 300w, https://audioboom.com/i/43107924/600x600/c 600w, https://audioboom.com/i/43107924/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #8da6c0; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43107924/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep26: FDA Approval Insights: Sunvozertinib in EGFR-Mutated Metastatic NSCLC: With Lyudmila Bazhenova, MD
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Dr Bazhenova discusses the FDA approval of sunvozertinib for patients with EGFR-mutated metastatic non–small cell lung cancer.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
6m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1759961100" data-format="short_date">Oct 08, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
6m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8787927-sequencing-efficacy-and-safety-data-may-further-evolve-the-role-of-fruquintinib-in-crc-with-ka"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43102530/75x75/c 75w, https://audioboom.com/i/43102530/150x150/c 150w, https://audioboom.com/i/43102530/300x300/c 300w, https://audioboom.com/i/43102530/600x600/c 600w, https://audioboom.com/i/43102530/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d4073; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43102530/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep25: Sequencing, Efficacy, and Safety Data May Further Evolve the Role of Fruquintinib in CRC: With Kanwal P. S. Raghav, MBBS, MD
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Dr Raghav discusses the role of fruquintinib in the treatment of adult patients with pretreated, metastatic colorectal cancer.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
9m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1759788600" data-format="short_date">Oct 06, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
9m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8786182-fda-approval-insights-maintenance-lurbinectedin-plus-atezolizumab-for-es-sclc-with-anne-chiang"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43094055/75x75/c 75w, https://audioboom.com/i/43094055/150x150/c 150w, https://audioboom.com/i/43094055/300x300/c 300w, https://audioboom.com/i/43094055/600x600/c 600w, https://audioboom.com/i/43094055/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d4073; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43094055/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep24: FDA Approval Insights: Maintenance Lurbinectedin Plus Atezolizumab for ES-SCLC: With Anne Chiang, MD, PhD; and Stephen Liu, MD
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Drs Chiang and Liu discuss the significance of the FDA approval of first-line maintenance therapy with lurbinectedin plus atezolizumab for ES-SCLC.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
13m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1759444525" data-format="short_date">Oct 02, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
13m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8785579-early-biomarker-testing-optimizes-tepotinib-use-in-nsclc-with-met-exon-14-skipping-mutations-wit"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43090935/75x75/c 75w, https://audioboom.com/i/43090935/150x150/c 150w, https://audioboom.com/i/43090935/300x300/c 300w, https://audioboom.com/i/43090935/600x600/c 600w, https://audioboom.com/i/43090935/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d4073; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43090935/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep23: Early Biomarker Testing Optimizes Tepotinib Use in NSCLC With MET Exon 14 Skipping Mutations: With Stephen Liu, MD
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Dr Liu discusses the 2 VISION trial of tepotinib for NSCLC harboring MET exon 14 skipping alterations, as well as the importance of biomarker testing.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
10m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1759358100" data-format="short_date">Oct 01, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
10m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8784382-expanding-jak-inhibitor-use-offers-increased-treatment-options-for-cytopenic-myelofibrosis-with"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43084902/75x75/c 75w, https://audioboom.com/i/43084902/150x150/c 150w, https://audioboom.com/i/43084902/300x300/c 300w, https://audioboom.com/i/43084902/600x600/c 600w, https://audioboom.com/i/43084902/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d4073; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43084902/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep22: Expanding JAK Inhibitor Use Offers Increased Treatment Options for Cytopenic Myelofibrosis: With Andrew Kuykendall, MD
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s episode, we had the pleasure of speaking with Andrew Kuykendall, MD, who gave an overview of the myelofibrosis treatment paradigm. Dr Kuykendall is an assistant member in the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, Florida.  
In our exclusive interview, Dr Kuykendall discussed the prevalence of patients with myelofibrosis who have mutations in JAK2, CALR...
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
11m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1759169328" data-format="short_date">Sep 29, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
11m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8783027-early-car-t-cell-therapy-data-highlight-therapeutic-potential-and-emerging-challenges-in-gi-cance"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43077988/75x75/c 75w, https://audioboom.com/i/43077988/150x150/c 150w, https://audioboom.com/i/43077988/300x300/c 300w, https://audioboom.com/i/43077988/600x600/c 600w, https://audioboom.com/i/43077988/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d4073; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43077988/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep21: Early CAR T-Cell Therapy Data Highlight Therapeutic Potential and Emerging Challenges in GI Cancers: With Kohei Shitara, MD
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In our exclusive interview, Dr Shitara discussed preliminary efficacy data with CAR T-cell therapy in gastrointestinal cancers; highlighted challenges related to durability of response, patient selection, and manufacturing logistics with these therapies; and outlined ongoing biomarker analyses exploring tumor microenvironment factors influencing resistance.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
9m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1758835736" data-format="short_date">Sep 25, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
9m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8782064-the-evolving-role-of-noncovalent-btk-inhibition-informs-cll-treatment-selection-with-asad-dean-md"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43073356/75x75/c 75w, https://audioboom.com/i/43073356/150x150/c 150w, https://audioboom.com/i/43073356/300x300/c 300w, https://audioboom.com/i/43073356/600x600/c 600w, https://audioboom.com/i/43073356/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d405a; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43073356/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep20: The Evolving Role of Noncovalent BTK Inhibition Informs CLL Treatment Selection: With Asad Dean, MD
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Dr Dean discusses the role of BTK inhibitors in the management of CLL and the importance of molecular profiling for treatment rechallenge decisions.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
16m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1758752102" data-format="short_date">Sep 24, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
16m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8779033-zidesamtinib-is-associated-with-cns-activity-and-low-rates-of-neurologic-aes-in-pretreated-ros1"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43057604/75x75/c 75w, https://audioboom.com/i/43057604/150x150/c 150w, https://audioboom.com/i/43057604/300x300/c 300w, https://audioboom.com/i/43057604/600x600/c 600w, https://audioboom.com/i/43057604/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d4073; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43057604/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep19: Zidesamtinib Is Associated With CNS Activity and Low Rates of Neurologic AEs in Pretreated ROS1+ NSCLC: With Alexander Drilon, MD
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Dr Drilon discusses the efficacy data and implications of the ARROS-1 trial, highlighted the mechanism of action of zidesamtinib in ROS1-positive NSCLC.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
8m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1758232500" data-format="short_date">Sep 18, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
8m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8778550-patient-characteristics-and-disease-factors-guide-the-use-of-dostarlimab-in-recurrent-endometrial"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43054965/75x75/c 75w, https://audioboom.com/i/43054965/150x150/c 150w, https://audioboom.com/i/43054965/300x300/c 300w, https://audioboom.com/i/43054965/600x600/c 600w, https://audioboom.com/i/43054965/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d405a; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43054965/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep18: Patient Characteristics and Disease Factors Guide the Use of Dostarlimab in Recurrent Endometrial Cancer: With Dana M. Chase, MD 
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In our exclusive interview, Dr Chase discussed the management of recurrent endometrial cancer, emphasizing the importance of biomarker profiles and previous therapies. For first recurrences, she explained that carboplatin and paclitaxel with pembrolizumab (Keytruda) or dostarlimab-gxly (Jemperli) is recommended for patients with mismatch repair–deficient (dMMR) disease, whereas those with MMR-p...
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
16m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1758150348" data-format="short_date">Sep 17, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
16m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8777796-expert-guidance-on-frequently-asked-questions-regarding-the-use-of-adcs-in-tnbc"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43051324/75x75/c 75w, https://audioboom.com/i/43051324/150x150/c 150w, https://audioboom.com/i/43051324/300x300/c 300w, https://audioboom.com/i/43051324/600x600/c 600w, https://audioboom.com/i/43051324/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d4073; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43051324/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep17: Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In this podcast, experts Aditya Bardia, MD, MPH, FASCO, Erika P. Hamilton, MD, and Virginia Kaklamani, MD, DSc, discuss frequently asked questions regarding the use of antibody-drug conjugates (ADCs) in triple-negative breast cancer (TNBC).
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
18m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1758039725" data-format="short_date">Sep 16, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
18m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8777762-establishing-the-rationale-for-adc-and-ici-combinations-in-tnbc"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43051159/75x75/c 75w, https://audioboom.com/i/43051159/150x150/c 150w, https://audioboom.com/i/43051159/300x300/c 300w, https://audioboom.com/i/43051159/600x600/c 600w, https://audioboom.com/i/43051159/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d4073; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43051159/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep16: Establishing the Rationale for ADC and ICI Combinations in TNBC
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In this podcast, experts Virginia Kaklamani, MD, DSc, and Tiffany A. Traina, MD, FASCO, discuss the rationale for and data to support combining TROP2-targeting antibody-drug conjugates (ADCs) with immune checkpoint inhibitors (ICIs) to treat triple-negative breast cancer (TNBC).
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
18m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1758036357" data-format="short_date">Sep 16, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
18m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8777411-cohort-analysis-shows-importance-of-early-onset-crc-awareness-and-investigation-with-evelyn-y-w"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43049431/75x75/c 75w, https://audioboom.com/i/43049431/150x150/c 150w, https://audioboom.com/i/43049431/300x300/c 300w, https://audioboom.com/i/43049431/600x600/c 600w, https://audioboom.com/i/43049431/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d4073; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43049431/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep15: Cohort Analysis Shows Importance of Early-Onset CRC Awareness and Investigation: With Evelyn Y. Wong, MD
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Dr Wong discusses the growing challenge of early-onset colorectal cancer and the insights from a recent cohort analysis conducted in Singapore. 
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
7m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1757972400" data-format="short_date">Sep 15, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
7m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8777369-expert-roundtable-and-panel-discussions-current-and-future-landscape-of-tnbc"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43049241/75x75/c 75w, https://audioboom.com/i/43049241/150x150/c 150w, https://audioboom.com/i/43049241/300x300/c 300w, https://audioboom.com/i/43049241/600x600/c 600w, https://audioboom.com/i/43049241/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d4073; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43049241/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep14: Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In this podcast, experts Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; and Tiffany A. Traina, MD, FASCO; discuss navigating between currently available therapies for patients with triple-negative breast cancer (TNBC). They also discuss the potential ramifications of ongoing clinical trials on future treatment paradigms.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
18m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1757969331" data-format="short_date">Sep 15, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
18m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8777335-dissecting-clinical-trial-and-real-world-data-for-adcs-in-tnbc"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43044415/75x75/c 75w, https://audioboom.com/i/43044415/150x150/c 150w, https://audioboom.com/i/43044415/300x300/c 300w, https://audioboom.com/i/43044415/600x600/c 600w, https://audioboom.com/i/43044415/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d4073; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43044415/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep13: Dissecting Clinical Trial and Real-World Data for ADCs in TNBC
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In this podcast, experts Filipa Lynce, MD, and Rita Nanda, MD, discuss recent clinical trial and real-world data for antibody-drug conjugates (ADCs) used to treat triple-negative breast cancer (TNBC).
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
20m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1757965920" data-format="short_date">Sep 15, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
20m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8776499-evaluating-the-latest-data-and-ongoing-trials-for-novel-adc-approaches-in-tnbc"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43044795/75x75/c 75w, https://audioboom.com/i/43044795/150x150/c 150w, https://audioboom.com/i/43044795/300x300/c 300w, https://audioboom.com/i/43044795/600x600/c 600w, https://audioboom.com/i/43044795/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d4073; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43044795/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep12: Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In this podcast, experts Aditya Bardia, MD, MPH, FASCO; and Erika P. Hamilton, MD, discuss recent efficacy and safety data of TROP2-targeted antibody-drug conjugate (ADC) plus immune checkpoint inhibitor combinations for advanced triple-negative breast cancer (TNBC).
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
17m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1757709720" data-format="short_date">Sep 12, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
17m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8776411-breaking-down-the-rationale-for-targeting-trop2-in-tnbc"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43044415/75x75/c 75w, https://audioboom.com/i/43044415/150x150/c 150w, https://audioboom.com/i/43044415/300x300/c 300w, https://audioboom.com/i/43044415/600x600/c 600w, https://audioboom.com/i/43044415/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d4073; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43044415/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep11: Breaking Down the Rationale for Targeting TROP2 in TNBC
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In this podcast, experts Filipa Lynce, MD, and Rita Nanda, MD, discuss unmet needs in triple-negative breast cancer (TNBC) and the rationale for using TROP2-targeting antibody-drug conjugates (ADCs) in this disease.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
15m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1757703459" data-format="short_date">Sep 12, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
15m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8776007-patient-characteristics-and-care-team-collaboration-influence-treatment-decision-making-in-cll-w"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43042449/75x75/c 75w, https://audioboom.com/i/43042449/150x150/c 150w, https://audioboom.com/i/43042449/300x300/c 300w, https://audioboom.com/i/43042449/600x600/c 600w, https://audioboom.com/i/43042449/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d4073; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43042449/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep10: Patient Characteristics and Care Team Collaboration Influence Treatment Decision-Making in CLL: With John N. Allan, MD; and Melissa Rubianes
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Allan and Rubianes discuss factors that influence treatment decision-making for patients with chronic lymphocytic leukemia. 
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
15m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1757628002" data-format="short_date">Sep 11, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
15m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8774844-tepotinib-efficacy-and-safety-profiles-underscore-the-importance-of-biomarker-directed-decision-m"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43036765/75x75/c 75w, https://audioboom.com/i/43036765/150x150/c 150w, https://audioboom.com/i/43036765/300x300/c 300w, https://audioboom.com/i/43036765/600x600/c 600w, https://audioboom.com/i/43036765/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d4073; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43036765/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep9: Tepotinib Efficacy and Safety Profiles Underscore the Importance of Biomarker-Directed Decision-Making in NSCLC: With Balazs Halmos, MD, MS
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Dr Halmos discusses the VISION trial, the significance of MET exon 14 skipping mutations in NSCLC, and the clinical utility of tepotinib in this disease.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
14m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1757457300" data-format="short_date">Sep 09, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
14m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8774145-recent-fda-approvals-and-ongoing-research-expand-treatment-options-for-soft-tissue-sarcoma-with"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43033298/75x75/c 75w, https://audioboom.com/i/43033298/150x150/c 150w, https://audioboom.com/i/43033298/300x300/c 300w, https://audioboom.com/i/43033298/600x600/c 600w, https://audioboom.com/i/43033298/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #a6daf3; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43033298/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep8: Recent FDA Approvals and Ongoing Research Expand Treatment Options for Soft Tissue Sarcoma: With Samantha A. Armstrong, MD; and Karine Tawagi, MD
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Drs Armstrong and Tawagi discuss key aspects of soft tissue sarcoma management. 
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
21m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1757371200" data-format="short_date">Sep 08, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
21m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8772472-clinical-trial-and-real-world-data-with-nalirifox-shape-the-future-of-pancreatic-cancer-care-wit"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43024825/75x75/c 75w, https://audioboom.com/i/43024825/150x150/c 150w, https://audioboom.com/i/43024825/300x300/c 300w, https://audioboom.com/i/43024825/600x600/c 600w, https://audioboom.com/i/43024825/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d4073; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43024825/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep7: Clinical Trial and Real-World Data With NALIRIFOX Shape the Future of Pancreatic Cancer Care: With Tara E. Seery, MD; Paul E. Oberstein, MD; and Priyadarshini Pathak, MBBS
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Drs Seery, Oberstein, and Pathak discuss data from the NAPOLI 3 trial of NALIRIFOX vs nab-paclitaxel and gemcitabine in treatment-naive pancreatic cancer.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
15m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1757024100" data-format="short_date">Sep 04, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
15m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8771892-advances-in-ctdna-testing-guide-clinical-decision-making-in-gi-cancer-management-with-scott-kope"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43021510/75x75/c 75w, https://audioboom.com/i/43021510/150x150/c 150w, https://audioboom.com/i/43021510/300x300/c 300w, https://audioboom.com/i/43021510/600x600/c 600w, https://audioboom.com/i/43021510/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d4073; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43021510/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep6: Advances in ctDNA Testing Guide Clinical Decision-Making in GI Cancer Management: With Scott Kopetz, MD, PhD, FACP
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Dr Kopetz discusses the value of ctDNA assays, trials that have shown prognostic implications with this type of assay, and the future of ctDNA research.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
22m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1756934700" data-format="short_date">Sep 03, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
22m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8771341-safety-and-quality-of-life-considerations-shape-adt-use-in-prostate-cancer-with-tanya-b-dorff-md"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43018588/75x75/c 75w, https://audioboom.com/i/43018588/150x150/c 150w, https://audioboom.com/i/43018588/300x300/c 300w, https://audioboom.com/i/43018588/600x600/c 600w, https://audioboom.com/i/43018588/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d4073; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43018588/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep5: Safety and Quality-of-Life Considerations Shape ADT Use in Prostate Cancer: With Tanya B. Dorff, MD
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Dr Dorff discusses the role of ADT in prostate cancer management, how this class has evolved, and the use of relugolix across treatment settings.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
15m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1756851940" data-format="short_date">Sep 02, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
15m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8770768-fda-approval-insights-dordaviprone-in-h3k27m-mutated-diffuse-midline-glioma-with-patrick-y-wen"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43015678/75x75/c 75w, https://audioboom.com/i/43015678/150x150/c 150w, https://audioboom.com/i/43015678/300x300/c 300w, https://audioboom.com/i/43015678/600x600/c 600w, https://audioboom.com/i/43015678/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #8da6c0; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43015678/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep4: FDA Approval Insights: Dordaviprone in H3K27M-Mutated Diffuse Midline Glioma: With Patrick Y. Wen, MD
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Dr Wen discussed the significance of the FDA approval of dordaviprone for patients at least 1 year of age with H3K27M-mutated diffuse midline glioma.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
10m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1756753200" data-format="short_date">Sep 01, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
10m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8769548-fda-approval-insights-taletrectinib-in-ros1-advanced-metastatic-nsclc-with-joel-neal-md-phd"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43009525/75x75/c 75w, https://audioboom.com/i/43009525/150x150/c 150w, https://audioboom.com/i/43009525/300x300/c 300w, https://audioboom.com/i/43009525/600x600/c 600w, https://audioboom.com/i/43009525/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d4073; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43009525/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep3: FDA Approval Insights: Taletrectinib in ROS1+ Advanced/Metastatic NSCLC: With Joel Neal, MD, PhD; and Christian Rolfo, MD, PhD
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Drs Neal and Rolfo discuss the significance of the FDA approval of taletrectinib for the treatment of locally advanced or metastatic, ROS1-positive NSCLC.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
14m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1756416300" data-format="short_date">Aug 28, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
14m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8768948-fda-approval-insights-zongertinib-in-her2-mutated-nsclc-with-ticiana-leal-md-and-misako-nagas"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43006539/75x75/c 75w, https://audioboom.com/i/43006539/150x150/c 150w, https://audioboom.com/i/43006539/300x300/c 300w, https://audioboom.com/i/43006539/600x600/c 600w, https://audioboom.com/i/43006539/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d4073; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43006539/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep2: FDA Approval Insights: Zongertinib in HER2-Mutated NSCLC: With Ticiana Leal, MD, and Misako Nagasaka, MD, PhD
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Leal and Nagasaka discussed the significance of the FDA approval of zongertinib for previously treated patients with HER2 TKD–mutant advanced NSCLC.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
16m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1756331460" data-format="short_date">Aug 27, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
16m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8768424-obe-cel-data-are-poised-to-refine-and-expand-the-all-treatment-paradigm-with-aaron-logan-md-ph"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43003642/75x75/c 75w, https://audioboom.com/i/43003642/150x150/c 150w, https://audioboom.com/i/43003642/300x300/c 300w, https://audioboom.com/i/43003642/600x600/c 600w, https://audioboom.com/i/43003642/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d4073; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43003642/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S14 Ep1: Obe-Cel Data Are Poised to Refine and Expand the ALL Treatment Paradigm: With Aaron Logan, MD, PhD; and Bijal Shah, MD, MS
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Drs Logan and Shah discussed where obe-cel currently fits into the B-ALL treatment paradigm and how the use of this agent might expand going forward.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
40m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1756244700" data-format="short_date">Aug 26, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
40m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8767918-suprame-trial-propels-the-development-of-tcr-based-therapy-in-cutaneous-melanoma-with-jason-luke"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43001214/75x75/c 75w, https://audioboom.com/i/43001214/150x150/c 150w, https://audioboom.com/i/43001214/300x300/c 300w, https://audioboom.com/i/43001214/600x600/c 600w, https://audioboom.com/i/43001214/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d4073; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43001214/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S13 Ep50: SUPRAME Trial Propels the Development of TCR-Based Therapy in Cutaneous Melanoma: With Jason Luke, MD
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Dr Luke discusses the rationale for evaluating IMA203 in cutaneous melanoma and what the PRAME trial findings may mean for the future of TCR therapy.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
7m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1756160100" data-format="short_date">Aug 25, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
7m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8766695-distinguishing-pathway-to-precision-for-c-met-and-met-alterations-in-nsclc"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/42995322/75x75/c 75w, https://audioboom.com/i/42995322/150x150/c 150w, https://audioboom.com/i/42995322/300x300/c 300w, https://audioboom.com/i/42995322/600x600/c 600w, https://audioboom.com/i/42995322/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d4073; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/42995322/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S13 Ep49: Distinguishing Pathway to Precision for c-Met and MET Alterations in NSCLC
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In this podcast, experts Erminia Massarelli, MD, PhD, MS; Jorge J. Nieva, MD; Sandip Patel, MD; and Ignacio I. Wistuba, MD, discuss new therapies for patients with c-Met–overexpressing non–small cell lung cancer.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
25m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1755875153" data-format="short_date">Aug 22, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
25m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8766271-refining-first-line-immunotherapy-strategies-in-hepatocellular-carcinoma-with-masatoshi-kudo-md"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/42993304/75x75/c 75w, https://audioboom.com/i/42993304/150x150/c 150w, https://audioboom.com/i/42993304/300x300/c 300w, https://audioboom.com/i/42993304/600x600/c 600w, https://audioboom.com/i/42993304/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d4073; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/42993304/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
S13 Ep48: Refining First-Line Immunotherapy Strategies in Hepatocellular Carcinoma: With Masatoshi Kudo, MD, PhD  
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s episode, we spoke with Masatoshi Kudo, MD, about the evolving treatment landscape in hepatocellular carcinoma (HCC) and how recent comparative analyses are helping refine the use of first-line immunotherapy-based regimens. Dr Kudo is a professor and chairman in the Department of Gastroenterology and Hepatology at Kindai University Faculty of Medicine in Osaka, Japan.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
7m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1755799474" data-format="short_date">Aug 21, 2025</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
7m
</div>
</div>
</div>
</a></div>

</template></turbo-stream>
  <turbo-stream action="replace" target="audio_clips_pagination"><template><turbo-frame loading="lazy" id="audio_clips_pagination" src="/channels/4965461-onclive-on-air/episodes.turbo_stream?list=1&amp;page=4"><div aria-hidden="true" class="card rounded-0 border-0 border-bottom">
<div class="card-body df align-items-center placeholder-glow text-black-50">
<div class="w-100">
<h5>
<div class="placeholder col-6"></div>
</h5>
<div class="placeholder placeholder-sm" style="width:15ch"></div>
</div>
<div class="mla">
<span class="placeholder placeholder-sm" style="width:4ch"></span>
</div>
</div>
</div>
<div aria-hidden="true" class="card rounded-0 border-0 border-bottom">
<div class="card-body df align-items-center placeholder-glow text-black-50">
<div class="w-100">
<h5>
<div class="placeholder col-6"></div>
</h5>
<div class="placeholder placeholder-sm" style="width:15ch"></div>
</div>
<div class="mla">
<span class="placeholder placeholder-sm" style="width:4ch"></span>
</div>
</div>
</div>
<div aria-hidden="true" class="card rounded-0 border-0 border-bottom">
<div class="card-body df align-items-center placeholder-glow text-black-50">
<div class="w-100">
<h5>
<div class="placeholder col-6"></div>
</h5>
<div class="placeholder placeholder-sm" style="width:15ch"></div>
</div>
<div class="mla">
<span class="placeholder placeholder-sm" style="width:4ch"></span>
</div>
</div>
</div>
<div aria-hidden="true" class="card rounded-0 border-0 border-bottom">
<div class="card-body df align-items-center placeholder-glow text-black-50">
<div class="w-100">
<h5>
<div class="placeholder col-6"></div>
</h5>
<div class="placeholder placeholder-sm" style="width:15ch"></div>
</div>
<div class="mla">
<span class="placeholder placeholder-sm" style="width:4ch"></span>
</div>
</div>
</div>
<div aria-hidden="true" class="card rounded-0 border-0 border-bottom">
<div class="card-body df align-items-center placeholder-glow text-black-50">
<div class="w-100">
<h5>
<div class="placeholder col-6"></div>
</h5>
<div class="placeholder placeholder-sm" style="width:15ch"></div>
</div>
<div class="mla">
<span class="placeholder placeholder-sm" style="width:4ch"></span>
</div>
</div>
</div>
<div class="visually-hidden">
<a href="/channels/4965461-onclive-on-air/episodes?list=1&amp;page=4">next page</a>
</div>
</turbo-frame></template></turbo-stream>
